A thrilling report has surfaced about the first baby being born as a result of a controversial fertilization technique, the spindle nuclear transfer. The procedure incorporates DNA from three “biological parents” to serve as the embryo’s genomic base, and is used to prevent mitochondrial diseases in infants.
There are people living among us, with capabilities we could easily call superpowers, and in most cases, they are not even aware of it. It turns out a tiny percentage of women actually develop a genetic condition called “tetrachromacy“, enabling them to see the world in hundred times more colors than the rest of us.
Humans have many phenotypic variations in eye color which is determined by multiple genes. So far, up to 16 genes have been associated with eye color inheritance. However, scientists from the Institute of Forensic Genetics at the University of Copenhagen discovered that the reason for blue eyes mainly lies in two genes: OCA2 and HERC2. This way they have shown that the earlier belief that blue eye color is a simple recessive trait is incorrect.
With all the talk about it in the scientific community, there is probably no surprise that this is yet another article discussing CRISPR. However, this may be one of the most profound discussions around the technology as it involves what could arguably be the potential flagship use of the gene editing tool – human therapy.
Advances in gene editing technology have spurred considerable progress towards a treatment for Duchenne muscular dystrophy (DMD). Although the disease is rare – affecting roughly 1 in 5,000 male births – its consequences are devastating: patients are confined to wheelchairs at an early age and often succumb to heart or respiratory failure in their twenties or thirties.
Cancerous cells are normally detected by biopsy which is an invasive and time consuming procedure.
The clover genome is very complicated and even though many scientists have tried to find the exact genes responsible for the four-leaf mutation, they haven’t been identified as of yet.